Skip to content

Study · Animal study (in vivo) · rat · 2017

8 results

Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model.

Nestvold J, Wang MY, Camilio KA, Zinöcker S, Tjelle TE, Lindberg A, Haug BE, Kvalheim G, Sveinbjørnsson B, Sveinbjørnsson B, Rekdal Ø

Oncoimmunology16 Jun 2017Cited by 40 (Europe PMC)

PMID28920000 (opens in a new tab)PMCIDPMC5593701 (opens in a new tab)DOI10.1080/2162402x.2017.1338236 (opens in a new tab)PepBankPUB-28920000
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with fibrosarcoma, intratumoral LTX‑315 produced complete tumor regression.

    In plain wordsIn rats with fibrosarcoma, LTX‑315 injected into tumors produced complete tumor regression.

    Peptide
    LTX-315
    Outcome
    DecreaseComplete tumor regression
    Study

    ratn: not reported in source

    fibrosarcoma
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · intratumoralAs given in this study (rat).

    Source sentences

    Summary
    In the present study, we demonstrate that intratumoral treatment with LTX-315 resulted in a complete regression and systemic immune response in a rat fibrosarcoma model.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In rats with fibrosarcoma, intratumoral LTX‑315 produced a systemic immune response.

    In plain wordsIn rats with fibrosarcoma, LTX‑315 injected into tumors produced a systemic immune response.

    Peptide
    LTX-315
    Outcome
    IncreaseSystemic immune response
    Study

    ratn: not reported in source

    fibrosarcoma
    Outcome group
    Immune response · Cancer
    Studied dose
    Dose not stated · intratumoralAs given in this study (rat).

    Source sentences

    Summary
    In the present study, we demonstrate that intratumoral treatment with LTX-315 resulted in a complete regression and systemic immune response in a rat fibrosarcoma model.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In rats with fibrosarcoma, the LTX‑315 treatment effect depended on T cells.

    In plain wordsIn rats with fibrosarcoma, the LTX‑315 treatment effect depended on T cells.

    Peptide
    LTX-315
    Outcome
    Not applicableT-cell dependence
    Study

    ratn: not reported in source

    fibrosarcoma
    Outcome group
    Immune response · Cancer
    Studied dose
    Dose not stated · intratumoralAs given in this study (rat).

    Source sentences

    Summary
    The treatment was T-cell dependent, and also resulted in an abscopal effect as demonstrated by the regression of distal non-treated lesions.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with fibrosarcoma, LTX‑315 treatment caused regression of distal untreated lesions.

    In plain wordsIn rats with fibrosarcoma, LTX‑315 treatment caused distant untreated tumors to regress.

    Peptide
    LTX-315
    Outcome
    DecreaseDistal untreated lesion regression
    Study

    ratn: not reported in source

    fibrosarcoma
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · intratumoralAs given in this study (rat).

    Source sentences

    Summary
    The treatment was T-cell dependent, and also resulted in an abscopal effect as demonstrated by the regression of distal non-treated lesions.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In rats with fibrosarcoma, LTX‑315 treatment produced significant CD8+ T-cell infiltration in treated lesions.

    In plain wordsIn rats with fibrosarcoma, LTX‑315 treatment produced significant CD8+ immune cell infiltration in treated tumors.

    Peptide
    LTX-315
    Outcome
    IncreaseCD8+ infiltration in treated lesions
    Study

    ratn: not reported in source

    fibrosarcoma
    Outcome group
    Immune response · Cancer
    Studied dose
    Dose not stated · intratumoralAs given in this study (rat).

    Source sentences

    Summary
    Significant infiltration of CD8+ T cells was observed in both treated and non-treated lesions, as shown by immunohistochemical and flow cytometric analysis.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In rats with fibrosarcoma, LTX‑315 treatment produced significant CD8+ T-cell infiltration in untreated lesions.

    In plain wordsIn rats with fibrosarcoma, LTX‑315 treatment produced significant CD8+ immune cell infiltration in untreated tumors.

    Peptide
    LTX-315
    Outcome
    IncreaseCD8+ infiltration in untreated lesions
    Study

    ratn: not reported in source

    fibrosarcoma
    Outcome group
    Immune response · Cancer
    Studied dose
    Dose not stated · intratumoralAs given in this study (rat).

    Source sentences

    Summary
    Significant infiltration of CD8+ T cells was observed in both treated and non-treated lesions, as shown by immunohistochemical and flow cytometric analysis.
  7. 07LabIn vitro (cells)Activity measurement

    In fibrosarcoma cells in vitro, LTX‑315 rapidly killed cells through lysis.

    In plain wordsIn cells, LTX‑315 rapidly killed fibrosarcoma cells through lysis.

    Peptide
    LTX-315
    Outcome
    IncreaseLytic cell killing
    Study

    ratn: not reported in source

    fibrosarcoma
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    LTX-315 rapidly killed the cells in vitro with a lytic mode of action followed by the subsequent release of Danger-Associated Molecular Pattern (DAMP) molecules such as HMGB1, ATP and Cytochrome c.
  8. 08LabIn vitro (cells)Mechanism

    In fibrosarcoma cells in vitro, lytic killing by LTX‑315 was followed by release of DAMP molecules including HMGB1, ATP and Cytochrome c.

    In plain wordsIn cells, LTX‑315 killing was followed by release of danger signals including HMGB1, ATP and Cytochrome c.

    Peptide
    LTX-315
    Outcome
    IncreaseDAMP release
    Study

    ratn: not reported in source

    fibrosarcoma
    Outcome group
    Immune response · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    LTX-315 rapidly killed the cells in vitro with a lytic mode of action followed by the subsequent release of Danger-Associated Molecular Pattern (DAMP) molecules such as HMGB1, ATP and Cytochrome c.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.